GUJARAT THEMIS BIOSYN SHARE PRICE

Promoted byJayshree D Patel, Gujarat Themis Biosyn Limited (GTBL) was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985. It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007. Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990. However, problems relating to purity levels, yield and imports put the company in the red and it became a BIFR case in 1990. Subsequently, Company was taken over by a group consisting of Lyka Labs, Themis Chemicals, Kopran and Cadila. Also, Yuhan Corp., South Korea, brought in technology and finance for running GTBL. During 1995-96 the paid-up share capital increased from Rs 11.25 crores to Rs 11.60 crores after allotment of 350,000 Equity shares of Rs 10 each at a premium of Rs 20 per share to the financial institutions by way of conversion of fund interst term loan. During the year 2019-20, installed capacity of rifamysin-S was increased to 90 mtpa and expansion of rifampicin was achieved to the maximum capacity of 120 mtpa. It also commenced operations of its new pharmaceutical division and launched a wide range of anti-tuberculosis products and other antibiotics in 2022. Company is presently engaged in the manufacturing of fermentation-based pharmaceutical intermediates and APIs. It is manufacturing Rifamycin S, which is an intermediate for manufacturing the drug Rifampicin and Rifamycin O, which is an intermediate for manufacturing the drug Rifaximin. The Company commenced its commercial production at its newly set up API Plant situated at 69/C, GIDC Industrial Estate, Vapi, in Valsad district of Gujarat with effect from 6 May, 2025. The multi-purpose synthetic and fermentation-based API plant has been established for the production of various Active Pharmaceutical Ingredients (APIs) and Intermediates for use in the pharmaceutical industry.

Gujarat Themis Biosyn share price as on 17 Dec 2025 is Rs. 384.5. Over the past 6 months, the Gujarat Themis Biosyn share price has increased by 10.97% and in the last one year, it has increased by 57.93%. The 52-week low for Gujarat Themis Biosyn share price was Rs. 208 and 52-week high was Rs. 479.

Promoted byJayshree D Patel, Gujarat Themis Biosyn Limited (GTBL) was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985. It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007. Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990. However, problems relating to purity levels, yield and imports put the company in the red and it became a BIFR case in 1990. Subsequently, Company was taken over by a group consisting of Lyka Labs, Themis Chemicals, Kopran and Cadila. Also, Yuhan Corp., South Korea, brought in technology and finance for running GTBL. During 1995-96 the paid-up share capital increased from Rs 11.25 crores to Rs 11.60 crores after allotment of 350,000 Equity shares of Rs 10 each at a premium of Rs 20 per share to the financial institutions by way of conversion of fund interst term loan. During the year 2019-20, installed capacity of rifamysin-S was increased to 90 mtpa and expansion of rifampicin was achieved to the maximum capacity of 120 mtpa. It also commenced operations of its new pharmaceutical division and launched a wide range of anti-tuberculosis products and other antibiotics in 2022. Company is presently engaged in the manufacturing of fermentation-based pharmaceutical intermediates and APIs. It is manufacturing Rifamycin S, which is an intermediate for manufacturing the drug Rifampicin and Rifamycin O, which is an intermediate for manufacturing the drug Rifaximin. The Company commenced its commercial production at its newly set up API Plant situated at 69/C, GIDC Industrial Estate, Vapi, in Valsad district of Gujarat with effect from 6 May, 2025. The multi-purpose synthetic and fermentation-based API plant has been established for the production of various Active Pharmaceutical Ingredients (APIs) and Intermediates for use in the pharmaceutical industry.

Gujarat Themis Biosyn share price as on 17 Dec 2025 is Rs. 384.5. Over the past 6 months, the Gujarat Themis Biosyn share price has increased by 10.97% and in the last one year, it has increased by 57.93%. The 52-week low for Gujarat Themis Biosyn share price was Rs. 208 and 52-week high was Rs. 479.